552331-47-2

Basic information

• Product Name: [1-BenzyloxyMethyl-2-(5-broMo-pyridin-3-yloxy)-ethyl]-carbaMic acid tert-butyl ester
• Synonyms: [1-BenzyloxyMethyl-2-(5-broMo-pyridin-3-yloxy)-ethyl]-carbaMic acid tert-butyl ester
• CAS NO: 552331-47-2
• Molecular Formula: C₂₀H₂₅BrN₂O₄
• Molecular Weight: 437.3275
• Mol File: 552331-47-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [1-BenzyloxyMethyl-2-(5-broMo-pyridin-3-yloxy)-ethyl]-carbaMic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [1-BenzyloxyMethyl-2-(5-broMo-pyridin-3-yloxy)-ethyl]-carbaMic acid tert-butyl ester(552331-47-2)
• EPA Substance Registry System: [1-BenzyloxyMethyl-2-(5-broMo-pyridin-3-yloxy)-ethyl]-carbaMic acid tert-butyl ester(552331-47-2)

Safety Data

• Hazardous Substances Data: 552331-47-2(Hazardous Substances Data)

Upstream product

• 74115-13-2 5-bromopyridine-3-ol 
• 79069-15-1 N-(tert-butyloxycarbonyl)-O-benzyl-L-serinol 

Downstream Products

• 882170-05-0 {(S)-1-Benzyloxymethyl-2-[5-((E)-2-pyridin-4-yl-vinyl)-pyridin-3-yloxy]-ethyl}-carbamic acid tert-butyl ester 

Relevant articles and documents

Discovery of trans-3,4′-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation

A novel series of Akt/PKB inhibitors derived from a screening lead (1) has been prepared. The novel trans-3,4′-bispyridinylethylenes described herein are potent inhibitors of Akt/PKB with IC50 values in the low double-digit nanomolar range against Akt1. Compound 2q shows excellent selectivity against distinct families of kinases such as tyrosine kinases and CAMK, and displays poor to modest selectivity against closely related kinases in the AGC and CMGC families. The cellular activities including inhibition of cell growth and phosphorylation of downstream target GSK3 are also described. The X-ray structure of compound 2q complexed with PKA in the ATP binding site was determined.

Kinase inhibitors

Compounds having the formula are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.